Retinal pigment epithelial tears after single administration of intravitreal bevacizumab for neovascular age-related macular degeneration

Klein R, Klein BEK, Linton KLP . Prevalence of age-related maculopathy. The beaver dam eye study. Ophthalmology 1992; 99: 933–943.

Kvanta A, Algvere PV, Berglin L, Seregard S . Subfoveal fibrovascular membranes in age-related macular degeneration expresses vascular endothelial growth factor. Invest Ophthalmol Vis Sci 1996; 37: 1929–1934.

Kliffen M, Sharma HS, Mooy CM, Kerkvliet S, de Jong PT . Increased expression of angiogenic growth factors in age-related maculopathy. Br J Ophthalmol 1997; 81: 154–162.

Krzystolik MG, Afshari MA, Adamis AP, Gaudreault J, Gragoudas ES, Michaud NA et al. Prevention of experimental choroidal neovascularization with intravitreal antivascular endothelial growth factor antibody fragment. Arch Ophthalmol 2002; 120: 338–346.

Gragoudas ES, Adamis AP, Cunningham Jr ET, Feinsod M, Guyer DR . VEGF Inhibition Study in Ocular Neovascularization Clinical Trial Group. Pegaptanib for neovascular age-related macular degeneration. N Engl J Med 2004; 351: 2805–2816.

Brown DM, Kaiser PK, Michels M, Soubrane G, Heier JS, Kim RY et al. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med 2006; 355: 1432–1444.

Rosenfeld PJ, Brown DM, Heier JS, Boyer DS, Kaiser PK, Chung CY et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 2006; 355: 1419–1431.

Rosenfeld PJ, Moshfeghi AA, Puliafito CA . Optical coherence tomography findings after an intravitreal injection of bevacizumab (avastin) for neovascular age-related macular degeneration. Ophthalmic Surg Lasers Imaging 2005; 36: 331–335.

Avery RL, Pieramici DJ, Rabena MD, Castellarin AA, Nasir MA, Giust MJ . Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Ophthalmology 2006; 113: 363–372.

Bashshur ZF, Bazarbachi A, Schakal A, Haddad ZA, El Haibi CP, Noureddin BN . Intravitreal bevacizumab for the management of choroidal neovascularization in age-related macular degeneration. Am J Ophthalmol 2006; 142: 1–9.

Spaide RF, Laud K, Fine HF, Klancnik Jr JM, Meyerle CB, Yannuzzi LA et al. Intravitreal bevacizumab treatment of choroidal neovascularization secondary to age-related macular degeneration. Retina 2006; 26: 383–390.

Rich RM, Rosenfeld PJ, Puliafito CA, Dubovy SR, Davis JL, Flynn Jr HW et al. Short-term safety and efficacy of intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Retina 2006; 26: 495–511.

Luke M, Warga M, Ziemssen F, Gelisken F, Grisanti S, Schneider T et al. Effects of bevacizumab on retinal function in isolated vertebrate retina. Br J Ophthalmol 2006; 90: 1178–1182, . e-pub 5 June 2006.

Maturi RK, Bleau LA, Wilson DL . Electrophysiologic findings after intravitreal bevacizumab (Avastin) treatment. Retina 2006; 26: 270–274.

Nicolo M, Ghiglione D, Calabria G . Retinal pigment epithelial tear following intravitreal injection of bevacizumab (Avastin). Eur J Ophthalmol 2006; 16: 770–773.

Meyer CM, Mennel S, Schmidt JS, Kroll P . Acute retinal pigment epithelial tear following intravitreal bevacizumab (Avastin) injection for occult choroidal neovascularisation secondary to age related macular degeneration. Br J Ophthalmol 2006; 90: 1207–1208.

Bakri SJ, Patel SP . Retinal pigment epithelial tear following intravitreal bevacizumab. Eye 2007; 21: 424–425.

Gelisken F, Ziemssen F, Voelker M, Bartz-Schmidt KU . Retinal pigment epithelial tear following intravitreal bevacizumab injection for neovascular age-related macular degeneration. Acta Ophthalmol Scand 2006; 84: 833–834.

Spandau UH, Jonas JB . Retinal pigment epithelium tear after intravitreal bevacizumab for exudative age-related macular degeneration. Am J Ophthalmol 2006; 142: 1068–1070.

Shah CP, Hsu J, Garg SJ, Fischer DH, Kaiser R . Retinal pigment epithelial tear after intravitreal bevacizumab injection. Am J Ophthalmol 2006; 142: 1070–1072.

Gamulescu MA, Framme C, Sachs H . RPE-rip after intravitreal bevacizumab (Avastin) treatment for vascularised PED secondary to AMD. Graefes Arch Clin Exp Ophthalmol 2007; 245: 1037–1040, e-pub 21 February 2007.

Chang LK, Sarraf D . Tears of the retinal pigment epithelium. An old problem in a new Era. Retina 2007; 27: 523–534.

Ronan SM, Yoganathan P, Chien FY, Corcostegui IA, Blumenkranz MS, Deramo VA et al. Retinal pigment epithelium tears after intravitreal injection of bevacizumab (avastin) for neovascular age-related macular degeneration. Retina 2007; 27: 535–540.

Chan CK, Meyer CH, Gross JG, Abraham P, Nuthi AS, Kokame GT et al. Retinal pigment epithelial tears after intravitreal bevacizumab injection for neovascular age-related macular degeneration. Retina 2007; 27: 541–551.

Shabeeba R, Hannan SR, Madhusudhana KC, Lotery AJ, Newsom RSB . Retinal pigment epithelial tear following bevacizumab for choroidal neovascular membrane due to age-related macular degeneration. Br J Ophthalmol 2007; 91: 977–978.

Mathews JP, Jalil A, Lavin MJ, Stanga PE . Retinal pigment epithelial tear following intravitreal injection of bevacizumab (avastin): optical coherence tomography and fluorescein angiographic findings. Eye 2007; 21: 1004–1005.

Macular Photocoagulation Study Group. Subfoveal neovascular lesions in age-related macular degeneration: guidelines for evaluation and treatment in the Macular Photocoagulation Study. Arch Ophthalmol 1991; 109: 1242–1257.

Verteporfin Roundtable Participants. Guidelines for using verteporfin (Visudyne) in photodynamic therapy for choroidal neovascularization due to age-related macular degeneration and other causes: update. Retina 2005; 25: 119–134.

Hoskin A, Bird AC, Sehmi K . Tears of detached retinal pigment epithelium. Br J Ophthalmol 1981; 65: 859–865.

Gass JD . Retinal pigment epithelial rip during krypton red laser photocoagulation. Am J Ophthalmol 1984; 98: 700–706.

Gelisken F, Inhoffen W, Partsch M, Schneider U, Kreissig I . Retinal pigment epithelial tear after photodynamic therapy for choroidal neovascularization. Am J Ophthalmol 2001; 131: 518–520.

Goldstein M, Heilweil G, Barak A, Loewenstein A . Retinal pigment epithelial tear following photodynamic therapy for choroidal neovascularization secondary to AMD. Eye 2005; 19: 1315–1324.

Dhalla MS, Blinder KJ, Tewari A, Hariprasad SM, Apte RS . Retinal pigment epithelial tear following intravitreal pegaptanib sodium. Am J Ophthalmol 2006; 141: 752–754.

Amselem L, Pulido JS, Diaz-Llopis M, Cervera E, Montero J . Retinal pigment epithelial tear following ranibizumab use. Eye 2007; 21(6): 846–847, e-pub ahead of print 26 January.

Casswell AG, Kohen D, Bird AC . Retinal pigment epithelial detachments in the elderly: classification and outcome. Br J Ophthalmol 1985; 69: 397–403.

Pauleikhoff D, Loeffert D, Spital G, Radermacher M, Dohrmann J, Lommatzsch A et al. Pigment epithelial detachment in elderly. Clinical differentiation, natural course and pathogenetic implications. Graefes Arch Clin Exp Ophthalmol 2002; 533–538.

Chuang EL, Bird AC . Bilaterality of tears of the retinal pigment epithelium. Br J Ophthalmol 1988; 72: 918–920.

Reynders S, Lafaut BA, Aisenbrey S, Broecke CV, Lucke K, Walter P et al. Clinicopathologic correlation in hemorrhagic age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol 2002; 240: 279–285.

Scupola A, Coscas G, Soubrane G, Balestrazzi E . Natural history of macular subretinal hemorrhage in age-related macular degeneration. Ophthalmologica 1999; 213: 97–102.